NYSE:BLCOMedical Equipment
Assessing Bausch + Lomb (BLCO) Valuation After Strong Q4 Growth And Vision 27 Margin Progress
Bausch + Lomb (BLCO) is back in focus after reporting record Q4 2025 revenue and adjusted EBITDA growth, supported by pharmaceuticals, premium intraocular lenses, contact lenses, and the Vision 27 margin improvement program.
See our latest analysis for Bausch + Lomb.
The record Q4 figures, guidance for 2026 revenue in the US$5.375b to US$5.475b range and fresh clinical attention on products like LUMIFY sit against a share price of US$18.30, with a 30 day share price return of 9.19% and a 1...